Shigella sonnei and Salmonella Typhi cause significant morbidity and mortality. We exploited the safety record of the oral, attenuated S. Typhi vaccine (Ty21a) by using it as a vector to develop a bivalent oral vaccine to protect against S. sonnei shigellosis and typhoid fever. We recombineered the S. sonnei form I O-antigen gene cluster into the Ty21a chromosome to create Ty21a-Ss, which stably expresses S. sonnei form I O antigen. To enhance survivability in the acid environment of the stomach, we created an acid-resistant strain, Ty21a-AR-Ss, by inserting Shigella glutaminase-glutamate decarboxylase systems coexpressed with S. sonnei form I O-antigen gene. Mice immunized intranasally with Ty21a-AR-Ss produced antibodies against S. sonnei and S. Typhi, and survived lethal intranasal S. sonnei challenge. This paves the way for proposed good manufacturing practices manufacture and clinical trials intended to test the clinical effectiveness of Ty21a-AR-Ss in protecting against S. sonnei shigellosis and typhoid fever, as compared with the current Ty21a vaccine.
Shigellosis (bacterial dysentery) is caused by Shigella spp. bacteria. There were 188 million human Shigella infections in 2010 [1] , affecting mainly children and causing 65 000 deaths. There are >40 serotypes of Shigella, but only a few responsible for the majority of shigellosis. In developing countries, Shigella flexineri accounts for most cases in children >5 years old, and S. sonnei is the second leading cause, at approximately 24% [2] . In developed countries S. sonnei is the leading cause of shigellosis, with 75% of the estimated approximately 500 000 annual US cases caused by S. sonnei [3, 4] . Moreover, drug-resistant S. sonnei infections associated with international travel have been increasingly reported [5, 6] . There is no safe and efficacious licensed vaccine against shigellosis [7] .
Protection against shigellosis is believed to be mediated primarily by antibodies to O polysaccharide (O antigen) [8] . Genes encoding S. sonnei O antigen are uniquely located on the virulence plasmid so that only cells that express O antigen (form I) are virulent [9] . Our strategy is to generate a bivalent vaccine against typhoid fever and S. sonnei shigellosis by administering the Salmonella Typhi Ty21a vaccine expressing the S. sonnei form I O antigen (Ss-f1-Oag).
The typhoid vaccine Ty21a (Vivotif) [10] administered orally during 1 week, affords sustained protection for 7 years, with efficacies ranging from 42% to 96% in Indonesian, Chilean, and Egyptian field trials [11] [12] [13] , and has had an excellent safety record in >200 million recipients [10, [14] [15] [16] [17] . Ty21a is nonpathogenic even when given at 100 times the standard dose [12] .
Ty21a expressing Ss-f1-Oag from a plasmid was shown to be protective in clinical trials [18] . However, because plasmid was unstable [19] and associated with lot-to-lot variation [18, 20] , development of this Ty21a-based shigellosis vaccine was halted.
The genetic instability associated with plasmid-borne immunogens has now been overcome. A recombinant Ty21a strain with a genome-integrated Ss-f1-Oag gene cluster induced serum antibodies against Ss-f1-Oag and Salmonella O 9,12 antigens and protected mice against lethal challenge [21] . However, the immunization and infection routes were through intraperitoneal injection, which is not the natural oral, mucosal route for Ty21a immunization and S. Typhi and S. sonnei infection. It is unknown whether the vaccine strain will be effective when immunization and challenge are administered through a mucosal route.
To induce protective immune responses, Ty21a must pass from the mouth to the ileum, where Ty21a invades M cells. The major barrier for a live, oral S. Typhi vaccine is the low pH in the stomach. Salmonella does not survive well at pH <3. Most Escherichia coli strains and Shigella spp. remain viable at low pH for several hours [22, 23] . This difference probably explains why only 10-100 Shigella cells are sufficient to cause infection, compared with approximately 10 5 colony-forming units (CFUs) of Salmonella. To facilitate the journey from mouth to ileum without being eliminated in the stomach, Ty21a is placed in enteric-coated capsules meant to withstand gastric low pH. The ability of E. coli and Shigella to withstand pH <2.5 primarily relies on an acid-resistant (AR) system known as the glutamate-dependent AR pathway [22, 24] consisting of the enzyme glutamate decarboxylase (GAD) and a membrane-bound antiporter. GAD consumes an intracellular proton to decarboxylate glutamate to produce γ-amino butyric acid (GABA) [25] [26] [27] [28] [29] . There are 2 isoforms of GAD, encoded by gadA and gadB, which are 98.7% identical in amino acid sequence and functionally redundant. The antiporter, encoded by gadC, pumps glutamate and GABA in and out of the cell [27] .
Recently, a newly discovered glutamine-dependent AR system was reported [30] . A previously uncharacterized bacterial glutaminase, encoded by ybaS, converts glutamine to glutamate in acidic conditions, releasing an ammonium that neutralizes an intracellular proton [30] . The antiporter for transporting substrate and product across cell membrane is also GadC [30] . Because the product of glutaminase is the substrate for GAD, we hypothesized that the glutaminase-GadC and GAD-GadC systems work in concert to convert a glutamine molecule into GABA, neutralizing 2 protons in the cell (Supplementary Figure 1 and [30] ). This concerted AR systems should function more efficiently than the GAD-GadC system alone [31] to enhance Ty21a viability in an acid environment.
We report the construction and characterization of Ty21a strains expressing Ss-f1-Oag alone or with the concerted glutaminase-GAD AR systems. Expression of the AR genes rendered our vaccine construct AR in vitro. The strains induced antibodies to Shigella and Salmonella O antigens when administered intranasally to mice, and the immunized mice survived intranasal lethal challenge with S. sonnei. These results provide the foundation for development of a cost-effective and easy-toadminister vaccine against shigellosis and typhoid fever.
METHODS

Bacterial Strains and Media
Bacterial strains used or generated are listed in Supplementary Table 1. Ty21a (Vivotif; Crucell Vaccines) was purchased. Seed banks were made in CY medium (1.2% yeast extract, 2% HyCase, 1.2% pepticase, 0.125% monosodium phosphate, 0.33% sodium chloride ( pH 7.2), with 0.2% glucose and 0.005% galactose), which is used for Vivotif production [10] . S. sonnei 53G was a gift from Dennis Kopecko [9] . Form I S. sonnei 53G were distinguished from form II based on morphological characteristic. Unless indicated, Ty21a and derivatives were grown in tryptic soy agar (TSA) or in tryptic soy broth (TSB) supplemented with 0.02% galactose, and S. sonnei strains were grown in TSA or TSB.
Recombinant Ty21a strains were generated using the λ-red recombineering technology [21, 32] . Polymerase chain reaction (PCR) fragments were amplified from a donor plasmid (Supplementary Table 1 ) by Phusion high-fidelity polymerase (New England BioLabs) using upstream primer TviD-2004F (5′-TGATTGCTAA CGTCATGAGC-3′) or GadC-1F (5′-ATGGCTACAT CAGTACAGAC-3′) and downstream primer VexA-1066R (5′-AGAAAGAATT AGTGCCGCGG-3′) and integrated in Ty21a harboring pKD46 [21, 32] . The Kan R selectable marker was deleted from the chromosomal integrants by transformation with pCP20 and selection for Kan S transformants, as described elsewhere [21, 33] . Chromosomal integration and selection marker eviction were confirmed using genomic PCR analysis and antibiotics sensitivity tests.
Plasmids
Plasmids are listed in Supplementary Table 1 , and details of plasmid construction using standard techniques and enzymes (New England BioLabs) are described in the Supplementary data. The integrity of all plasmids generated in this study was confirmed by DNA sequencing.
Assays
Methods for assays used in this study are described in detail in the Supplementary data.
Animal Immunization
Mice (4-8-week old female BALB/c mice; Jackson Laboratory) were maintained at Bioqual. They were immunized and assessed according to a protocol [34] approved by the Bioqual Laboratory Animal Care and Use Committee. On the day of immunization, overnight cultures of bacterial strains grown in CY medium or CY medium supplemented with 1% trehalose and 0.75% arabinose (AR activated) were harvested and resuspended in phosphate-buffered saline to a target concentration of 1 × 10 11 CFUs/mL. Mice anesthetized by isoflurane were intranasally inoculated with 5 μL of bacterial suspension at the anterior of each naris. Serum samples were collected a day before the first immunization, and 2 weeks after each immunization.
S. sonnei Challenge
First, 3-6 single colonies of form I S. sonnei 53G were pooled to inoculate into TSB and allowed to grow until mid-log phase (optical density at 600 nm [OD 600 ], approximately 1.0). Cells were resuspended in phosphate-buffered saline to a targeted concentration of 1 × 10 11 CFUs/mL, and 10 µL was used to inoculate each mouse intranasally. Mice were monitored daily for 14 days after infection.
Statistical Analyses
All tests were 2 sided and performed using R software (version 3.2.3) with stat and survival (2.38-3) packages.
RESULTS
Stable Integration and Expression From Ty21a Chromosome
We constructed a recombinant Ty21a with stable chromosomally integrated Ss-f1-Oag gene cluster between the tviD and vexA open reading frames (ORFs) ( Figure 1A ) [21, 32, 33] . This construct, though similar to what has been previously described [21] , is different in that the gene cluster was amplified from genomic DNA of S. sonnei 53G form I and initiated from the conserved 5′ border of O-antigen clusters [35] ( Figure 1B ). We included the wzz ORF that was not previously expressed [21] , because wzz expression facilitated uniform distribution of Ss-f1-Oag on Ty21a, similar to the distribution of Ss-f1-Oag on S. sonnei (Supplementary Figure 2C , row 2). Our final vaccine strain, designated Ty21a-Ss, did not have the antibiotic resistance marker. Chromosomal integration and integrity of the Ss-f1-Oag gene cluster was confirmed by DNA sequencing, and only 3 nonsynonymous single-nucleotide polymorphisms were identified, in comparison with the published sequence pSs046 [35] . Sequencing of independently amplified PCR fragments from S. sonnei 53G genomic DNA demonstrated that these polymorphisms were present in S. sonnei 53G; we believe they arose from natural variation between laboratory isolates. We hypothesized that expression of the AR genes in Ty21a would make a better vaccine. Because regulation of AR gene expression is not fully understood, we put these genes under the regulation of the arabinose-controlled promoter, P ara , which responds quickly to the arabinose-bound transcription factor, AraC, which activates robust gene transcription. We used PCR to amplify Shigella ybaS and the gadBC coding sequences, fused them, and placed them under P ara to create a polycistronic AraC-P ara -YbaS-GadBC expression cassette. This cassette was integrated into the Ty21a chromosome to replace the tviE ORF. The resulting strain was then used for stable integration of the Ss-f1-Oag expression cassette, using gadC and vexA as homologous sequences for recombination ( Figure 1C) , and the Kan R marker was evicted. The resulting final, markerless, strain was designated Ty21a-AR-Ss.
Cell Surface Expression
We examined Ss-f1-Oag expression by means of Western blots (Figure 2A and 2B) and immunofluorescence assays ( Figure 2C ). Because the arabinose-controlled AR genes in Ty21a-AR-Ss are located 5′ to the Ss-f1-Oag gene cluster, we also examined form I O-antigen expression in the presence of 0.75% arabinose in the culture medium, mimicking AR-activating conditions. Ss-f1-Oag in S. sonnei 53G is expressed as a ladder of 2-sugar repeats that is lipopolysaccharide (LPS) core linked, and a smear at higher molecular weight, which is linked to group 4 capsule ( Figure 2A ). Ty21a-Ss expressed Ss-f1-Oag, and Ty21a did not (Figure 2A and 2C). As described elsewhere [21, 36] , most Ss-f1-Oag was expressed in the form that is capsule linked in Ty21a-Ss. Ty21a-Ss expressed the Ss-f1-Oag uniformly on the cell surface, similar to the native form expressed on S. sonnei 53G form I (Supplementary Figure 2C(2) ). Ty21a-AR-Ss expressed Ss-f1-Oag of similar levels and morphologically similar to that from Ty21a-Ss, regardless of presence of arabinose (Figure 2A, lanes 3 and 4 , and 2C, rows 3 and 4). The expression levels of Salmonella groups O9,12-antigen from Ty21a-Ss and Ty21a-AR-Ss strains were comparable to those of Ty21a (Figure 2B) ; the S. sonnei and S. Typhi O antigens coexisted on the cell surface ( Figure 2C ).
Acid Resistance
To confirm that the integrated AR genes expressed on induction were enzymatically active, we subjected Ty21a-AR-Ss to glutaminase and GAD assays [37] , with slight modifications. Triton X-100 was omitted from the original GAD and glutaminase reagents. Therefore, only when a functional GadC transporter was present could glutamine or glutamate be transported into the cell for enzyme utilization. Bromocresol green was the pH indicator. Ty21a and Ty21a-Ss were unable to use glutamine or glutamate to increase pH in the test reagent; the reactions remained yellow after incubation at 37°C for 30 minutes ( Figure 3A , lanes 1 and 2). Reactions containing Ty21a-AR-Ss grown in the absence of arabinose turned slightly bluish-green, indicating a low-level leaky expression of the AR enzymes ( Figure 3A , lane 3). When grown in the presence of arabinose, Ty21a-AR-Ss turned the assay reagents strongly bluish-green, indicating robust expression of enzymatically active AR genes ( Figure 3A , lane 4); Ty21a-AR-Ss expressed functional AR genes in a transcriptionally controlled manner. We next tested the ability of Ty21a-AR-Ss to survive at pH 2.5. Because Salmonella needs acidic culture conditions to induce acid tolerance response, a prerequisite for AR [38] , 1% trehalose was included for acid fermentation in addition to 0.75% arabinose. Bacterial strains were grown to stationary phase, and cultures diluted 1:20 in acid medium at pH 2.5 in the presence of 1.5 mmol/L glutamine. Reactions were incubated at 37°C with agitation, and viability was examined at the indicated time points ( Figure 3B ). S. sonnei 53G form II maintained approximately 100% viability after 1-hour incubation at pH 2.5. In contrast, Ty21a survived poorly at this condition: viability was reduced by >10 Increasing glutamine concentration to 6 mmol/L improved survival for Ty21a-AR-Ss; cell survival at 45 minutes improved to approximately 50%. Ty21a recovered from the acid exposure was slow growing and lost expression of the Salmonella O antigen, whereas Ty21a-AR and Ty21a-AR-Ss maintained levels of Oantigen expression comparable to levels before acid exposure ( Figure 3C ). Expression of the concerted glutaminase-GAD AR systems improved AR and cell viability of recombinant Ty21a strains.
Stability
We generated genetic seedbanks for Ty21a-Ss and Ty21a-ARSs. All microbiological, biochemical, immunological, genetic, and molecular properties were as expected ( Figure 4A ). Cells were grown under nonselective conditions for 200 generations, and 100 colonies from each culture were subjected to colony immunoblot analysis for Ss-f1-Oag expression. All 100 colonies of Ty21a-Ss ( Figure 4B ) and Ty21a-AR-Ss ( Figure 4C ) tested retained Ss-f1-Oag expression, demonstrating 100% stability of the chromosomally integrated genes after 200 generations of growth.
Immunogenicity
To assess whether Ty21a-Ss and Ty21a-AR-Ss were immunogenic when administered via the mucosal route, we immunized , and Ty21a-AR-Ss + ARA (lane 4) were harvested, and assays were performed as described in Methods. After 30-minute incubation at 37°C, a yellow color indicates no activity and a blue-greenish color indicates positive for the indicated enzymatic activity. B, Viability assay at pH 2.5. Cells from indicated saturating cultures grown in tryptic soy broth supplemented with 1% trehalose and 0.75% arabinose were diluted 1:20 into acid medium, and viability was measured as described in Methods. C, Colonies recovered from acid challenge were grown in tryptic soy broth at 37°C overnight. O antigens were extracted from the overnight cultures for Western blot analyses using anti-Ty21a and anti-Shigella sonnei form I antiserum. Experimental details are described in the Supplementary data. Sizes of the molecular weight standard in KDa are indicated to the left. Abbreviation: ARA, arabinose.
groups of 10 mice intranasally with doses (1 × 10
9 CFUs) of Ty21a, Ty21a-Ss, Ty21a-AR-Ss (AR gene not expressed), and Ty21a-AR-Ss grown in the presence of trehalose and arabinose (AR genes activated; referred to as Ty21a-AR-Ss + ARA) at 2-week intervals. Serum immunoglobulin (Ig) G antibody responses against Ss-f1-Oag at 2 weeks after doses 2, 3, and 4 were assessed with enzyme-linked immunosorbent assay.
Results are reported as the geometric mean (GM) OD 1.0 (serum dilution at which the OD was 1.0; Figure 5A ). Mice immunized with Ty21a-Ss, Ty21a-AR-Ss, and Ty21a-ARSs + ARA produced higher serum IgG antibodies against Ssf1-Oag than the Ty21a control or naive mice, and antibodies increased with increased numbers of immunizations (P < .05; Wilcoxon rank test). At 2 weeks after dose 4, the GM OD 1.0 to Ss-f1-Oag of mice immunized with Ty21a-Ss, Ty21a-ARSs, and Ty21a-AR-Ss + ARA was 7909.5 (range, 2560-21 700), 7202.4 (3363-15 910), and 23 020.8 (8521-71 575), respectively. We also assessed antibodies to Salmonella groups O 9,12-antigens, the native O antigens expressed on Ty21a surface that induce protective immunity against typhoid fever ( Figure 5B ). For mice immunized with Ty21a, the GM OD 1.0 of serum IgG antibodies to Salmonella O 9,12-antigens was 53.9 (range, 1-864), 54.5 (1-545), and 328.3 (72-2295) at 2 weeks after doses 2, 3, 4, respectively. Ty21a-Ss, Ty21a-AR-Ss, and Ty21a-AR-Ss + ARA induced anti-Salmonella O 9,12 -antigen serum IgG at comparable levels. At 2 weeks after dose 4, the GM OD 1.0 was 421.6 (range 98-1241), 182.3 (range (74-1030), and 426.8 (range 78-2539) for Ty21a-Ss, Ty21a-AR-Ss, and Ty21a-AR-Ss + ARA. Naive mice had a GM OD 1.0 of 13.6 (range, 1-38).
Protective Efficacy
We challenged the immunized mice 6 weeks after dose 4 with S. sonnei 53G form I, using intranasal instillation. Only 3 of 9 control mice immunized with Ty21a survived the challenge, but 7 of 10, 9 of 10, and 9 of 10 mice immunized with Ty21a-Ss, Ty21a-AR-Ss, and Ty21a-AR-Ss + ARA, respectively, survived and remained healthy throughout the 14-day monitoring Figure 4 . Characterization of Ty21a-Ss and Ty21a-AR-Ss seed banks. A, Two random vials from each of the seed banks were characterized as described elsewhere [10] , with additional assays designed specifically for the integrated genes. Ty21a (Vivotif ) and Salmonella enterica serovar Typhi Ty2 were controls. GAD, glutamate decarboxylase; H 2 O 2 , hydrogen peroxide; PCR, polymerase chain reaction; rDNA, ribosomal DNA. B, C, A representative anti-Ss form I O antigen colony blot of Ty21a-Ss (B) and Ty21a-AR-Ss (C) after 200 generations of growth is shown, demonstrating 100% stability of the transgene. period ( Figure 6 ). The protective efficacies were 55.2%, 85.1%, and 85.1%, respectively, for Ty21a-Ss, Ty21a-AR-Ss, and Ty21a-AR-Ss + ARA. For the 2 groups that received the Ty21a-AR-Ss constructs, the difference between Ty21a control and immunized mice was significant (P = .02; 2-tailed Fisher exact test).
DISCUSSION
Oral immunization with Ty21a expressing Ss-f1-Oag from a plasmid protected humans against S. sonnei diarrhea and dysentery [18] . However, the plasmid-based construct was unstable with DNA rearrangements and deletions of plasmid material probably causing lot-to-lot variation [19] . Chromosomal Figure 5 . Ty21a-Ss and Ty21a-AR-Ss immunized through a mucosal route generated high antibody responses to Shigella sonnei form I Ty21a O antigens. Mice were immunized intranasally with 1 × 10 9 colony-forming units of Ty21a (black), Ty21a-Ss (blue), Ty21a-AR-Ss (red), or Ty21a-AR-Ss + ARA (green) 4 times at 2-week interval. Serum samples were collected 2 weeks after doses 2, 3, and 4, and antibody responses to extracted S. sonnei lipopolysaccharide (LPS) (A) or Ty21a LPS (Salmonella groups 9,12 O antigens) (B) were measured using enzyme-linked immunosorbent assay (ELISA) to determine the serum dilution at which the optical density was 1.0 (OD 1.0). Data were collected using Softmax 5.0 software and were fit to a 4-parameter logistic curve. Serum samples from 5 unimmunized, naive mice (gray) of the same age were also collected and measured as negative controls. Each point represents an individual mouse, and the intensity of the point indicates whether the mouse was protected (black) or unprotected (gray) from a lethal S. sonnei 53G form I infection. The geometric mean for each group is indicated by a horizontal bar. Abbreviations: ARA, arabinose; IgG, immunoglobulin G. integration using bacterial recombineering techniques addressed this issue [21] . Indeed, our recombinant vaccine strains maintained stable and robust expression of Ss-f1-Oag for a minimum of 200 generations ( Figure 4B and 4C) .
Protection against typhoid fever by immunization with Ty21a was excellent when the vaccine was administered as a buffered liquid [13] and higher than with enteric-coated capsules [16, 39] . This increased efficacy was probably due to more viable Ty21a making it through the acid environment of the stomach into the small intestine when administered in a buffered liquid. Conferring AR to Ty21a should allow for even more viable bacteria reaching the small intestine, leading to improved immunogenicity and protective efficacy at the same dose of Ty21a. Ty21a-AR-Ss maintained approximately 50% viability at pH 2.5 for 30-45 minutes in vitro. In comparison, viability of Ty21a was reduced by >10 2 -fold at 15 minutes and >10 7 -fold by 30 minutes. The half-life for gastric emptying time in humans is about 26-45 minutes [40, 41] .
Importantly, coexpression of the AR genes did not affect expression of Ss-f1-Oag and native Ty21a O antigen in vitro (Figure 2) or immunogenicity of the bacterial strain in vivo (Figures 5 and 6 ). Ty21a quickly lost viability and O-antigen expression on exposure to acid, but Ty21a-AR-Ss maintained the same levels of O-antigen expression ( Figure 3C ). Moreover, we observed slightly better antibody responses and higher protective efficacy in mice immunized with Ty21a-AR-Ss than in those immunized with Ty21a-Ss, especially when the AR genes were activated (Ty21a-AR-Ss + ARA). This was probably because culture conditions for AR gene induction favored cell viability. Even though we immunized mice with similar amounts of bacterial cells (determined by OD 600 ), the viable counts for the Ty21a-AR-Ss + ARA were always higher, but no more than 2-fold higher than that of the other 3 groups. By rendering Ty21a AR, we expect increased bioavailability, which should increase immunogenicity and protective efficacy.
Humans become infected with S. Typhi by ingestion of the bacteria. Ty21a is an orally administered vaccine. However, it does not infect mice, making it difficult to assess immunization by oral administration. Thus, testing of immunogenicity and protective efficacy in mice after intraperitoneal administration was undertaken [21] . This could be misleading. LPS is highly immunogenic when administered intraperitoneally but not when administered by mucosal routes [42] . Furthermore, deaths from intraperitoneal inoculation of gram-negative bacteria are related to the toxic effects of endotoxin [43] , which may be distinct from the effects of invasive Shigella infection in human intestinal epithelium.
The route for immunization and challenge of a Ty21a-based vaccine is ideally oral. However, because Ty21a, S. Typhi, [44] , and Shigella spp. do not infect normal mice when administered orally, an intranasal route has been established in mice to evaluate mucosal immune responses to live attenuated bacterial vaccines [34, 45] . The serum antibody responses in mice were about 10-fold lower using the intranasal compared with the intraperitoneal route (unpublished data). Nevertheless, using this approach, we demonstrated that Ty21a-Ss and Ty21a-AR-Ss stimulated antibodies against both S. sonnei and Salmonella LPS. Most importantly, 9 of 10 mice immunized intranasally with Ty21a-AR-Ss or Ty21a-AR-Ss + ARA vaccine, compared with 3 of 9 immunized with Ty21a alone, survived a lethal intranasal infection with S. sonnei 53G (protective efficacy for each, 85.1%).
Ty21a protects for up to 7 years [12] . We expect similar protection with the typhoid-shigellosis combination vaccine. Ty21a can be foam dried, providing for temperature stabilization and a potential shelf life of 5-10 years [46] , which will facilitate storage and distribution. Most importantly, Ty21a is extremely safe. To our knowledge, there have been no reports of bacteremia or Ty21a-associated postvaccination reactive arthritis, a potential problem with other live attenuated vectors, including nontyphoid Salmonella, Shigella, and Yersinia. We do not foresee safety concerns with inclusion of the AR genes. These genes are present and functional in avirulent strains of E. coli and Shigella spp., such as S. sonnei 53G form II ( Figure 3B ). Therefore, they are insufficient to cause disease on their own. The AR genes are stably integrated into the Ty21a genome and placed under an artificially inducible promoter. These properties make horizontal transfer to and gene activation in another bacterium extremely unlikely. Finally, except for the expression of the AR and Ss-f1-Oag transgenes, Ty21a-AR-Ss displays the Figure 6 . Mice immunized with Ty21a-Ss vaccine strains were protected from lethal Shigella sonnei 53G form I infection. All mice were challenged 6 weeks after vaccine dose 4 with a lethal infection of S. sonnei 53G form I by nasal instillation and monitored daily for 14 days. Each mouse was calculated to have received 1.2 × 10 9 colony-forming units, corresponding to 24 times the 50% lethal dose determined by pilot infection experiments with naive mice. Only 3 of 9 mice immunized with Ty21a survived, compared with 7 of 10 immunized with Ty21a expressing Ss-f1-Oag (Ty21a-Ss), 9 of 10 immunized with Ty21a expressing Ss-f1-Oag but not the AR genes (Ty21a-AR-Ss), and 9 of 10 immunized with Ty21a expressing Ss-f1-Oag and AR genes (Ty21a-AR-Ss + ARA). The difference in survival rates among all 4 groups was analyzed by means of 2-tailed Fisher exact test (P = .02). The difference in survival rates for all immunized mice versus controls was 25 of 30 versus 3 of 9 (P = .008). That for Ty21a-AR-Ss (with or without arabinose) versus Ty21a control was 9 of 10 versus 3 of 9 (P = .02). That for Ty21a-Ss versus Ty21a control was 7 of 10 versus 3 of 9 (P = .18). Abbreviation: ARA, arabinose. microbiological, biochemical, immunological, and genetic properties of Ty21a (Figure 4) , demonstrating that expression of the AR genes has no effect on Ty21a attenuation. This finding is similar to a recently reported study with the GAD-GadC AR system, but not the glutaminase-GadC system we also included [31] . We cannot directly compare our results because the viability of the Ty21a control after acid challenge was lower in our experiments.
The recent Global Enteric Multicenter Study (GEMS) field study of 1130 Shigella spp. concluded, "A quadrivalent vaccine with O-antigens from S. sonnei, S. flexneri 2a, S. flexneri 3a, and S. flexneri 6 can provide broad direct coverage against these most common serotypes and indirect coverage . . . through shared S. flexneri group antigens . . ." (up to 88% coverage) [2] . Our goal is to develop such a quadrivalent vaccine.
However, S. sonnei is responsible for 75% of all cases of shigellosis in the United States [4] and most cases in Israel [47] , Thailand [48] , and Southern Vietnam [49] . While developing the 3 other constructs for the quadrivalent vaccine, we plan to move forward in parallel to good manufacturing practices manufacture of our AR Ty21-AR-Ss vaccine (TyOraSs). The next step will be to prove that it is safe, immunogenic, and protective against shigellosis and typhoid in humans.
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